Emergent BioSolutions Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on September 30, 2021. The report details a material definitive agreement entered into on the same date regarding the procurement of anthrax vaccine doses for the U.S. government.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the period. The only specific financial figure disclosed is the value of a new contract modification.
- New Contract Value: Approximately $399 million.
- Contract Subject: Procurement of additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant).
- Delivery Timeline: Over the next 18 months.
- Destination: Strategic National Stockpile.
Material Changes
The material change reported is the execution of Modification No. 11 to the existing AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. This modification expands the scope of the existing agreement to include the additional $399 million in procurement.
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of the contract modification. The filing notes that the full text of the modification, with redactions for confidential information, will be filed as an exhibit to the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021. No specific risks, contingencies, or forward-looking guidance beyond the contract terms are detailed in this specific 8-K filing.
Key Facts for Investor Verification
- Verify the full terms of Modification No. 11 in the upcoming Form 10-Q exhibit.
- Confirm the specific delivery schedule and milestones for the $399 million contract over the 18-month period.
- Assess the impact of this contract on the company's future revenue recognition and cash flow projections.
- Review the company's capacity to fulfill the additional AV7909 dose requirements within the specified timeline.